Looking for research-grade compounds?
Epithalon peptide research is built around a fundamental question in cell biology: what happens when the protective caps on a cell’s chromosomes wear down? Epithalon — also spelled Epitalon — is a synthetic tetrapeptide of just four amino acids (Ala-Glu-Asp-Gly, abbreviated AEDG) reported in cell culture to switch telomerase back on in human somatic cells that normally show no telomerase activity at all. That single finding, published in 2003, is why this tiny pineal-derived peptide still anchors discussions of telomere biology more than two decades later. This profile separates what the laboratory record actually shows from what it does not: the in vitro telomerase data, an independent 2025 replication with an important caveat, the pineal work in primates, an honest reading of the rodent lifespan studies, and the compound’s current U.S. regulatory position. Researchers sourcing the compound can find the Epithalon research peptide in the Apex catalog, supplied strictly for laboratory research use.
Epithalon is a synthetic tetrapeptide developed at the St. Petersburg Institute of Bioregulation and Gerontology under Professor Vladimir Khavinson, as part of the Russian “peptide bioregulator” research program. It was designed to reproduce the active sequence attributed to Epithalamin, a complex peptide preparation extracted from bovine pineal glands. The synthetic version replaces a variable natural extract with a single, chemically defined molecule that can be manufactured by solid-phase peptide synthesis, verified analytically, and studied reproducibly — the same reason the field moved toward defined sequences generally, as covered in our guide to what peptides are.
| Property | Value |
|---|---|
| Sequence | Ala-Glu-Asp-Gly (AEDG) |
| Synonyms | Epitalon, Epithalone |
| Molecular formula | C14H22N4O9 |
| Molecular weight | 390.35 g/mol |
| CAS number | 307297-39-8 |
| Origin | Synthetic analogue of the pineal preparation Epithalamin |
| FDA approval status | Not FDA-approved for any indication |
| Research class | Tetrapeptide bioregulator / telomerase research compound |
At 390 daltons, Epithalon is one of the smallest named research peptides in common circulation — closer in size to a small molecule than to peptides such as semaglutide (4,114 Da). That matters analytically: a four-residue sequence means deletion sequences and variants sit very close to the parent compound on a chromatogram, which makes HPLC purity testing and mass spectrometry both important rather than either one alone.
The single most common error in Epithalon content is treating Epithalon and Epithalamin as interchangeable. They are not.
When a claim traces back to a human cohort, it almost always belongs to Epithalamin. When a claim traces back to telomerase activation in cultured fibroblasts, it belongs to Epithalon. Keeping those two records separate is the difference between an accurate profile and marketing copy, and it is the standard this article applies throughout.
Telomeres are repetitive DNA sequences that cap chromosome ends and protect coding DNA during replication. Because DNA polymerase cannot fully copy the end of a linear chromosome, telomeres shorten with most cell divisions. When they become critically short, the cell typically enters replicative senescence — the Hayflick limit — or triggers DNA-damage responses.
Telomerase is the enzyme that can extend telomeres, using its catalytic subunit (hTERT in humans) and an internal RNA template. It is active in germline and stem cell compartments but repressed in most adult somatic cells, which is why a compound reported to reactivate it in ordinary somatic cells attracts sustained attention. The pathway also cuts both ways: telomere maintenance is a normal feature of stem cells, but telomerase reactivation and the alternative lengthening of telomeres (ALT) pathway are also mechanisms cancers use. Serious readings of this literature have to hold both facts at once.
The foundational Epithalon paper is Khavinson, Bondarev and Butyugov (Bulletin of Experimental Biology and Medicine, 2003; PMID 12937682). Adding Epithalon to a telomerase-negative human fetal fibroblast culture induced expression of the telomerase catalytic subunit, measurable telomerase enzymatic activity, and telomere elongation. In the follow-on culture work from the same institute, treated fibroblast populations continued dividing beyond the 44th passage, while control populations terminated at the 34th passage — that is, the treated cultures surpassed the Hayflick limit, with telomere lengths restored to levels comparable to the original culture.
Two limitations belong next to that result in any honest summary. First, the original reports are short communications from a single research institute, without the sample sizes and statistical reporting expected of a modern replication study. Second, cell culture is not an organism: telomere elongation in a dish does not, by itself, establish any effect in a living animal or a person. For roughly twenty years, the finding stood largely unreplicated by independent laboratories — which is what makes the 2025 work below significant.
In 2025, researchers at Brunel University London and the Royal Brompton Hospital published a study in Biogerontology examining Epitalon across normal human cell lines (HMEC epithelial cells and IBR.3 fibroblasts) and two breast cancer cell lines (21NT and BT474). In the normal lines, they reported dose-dependent telomere length increases associated with increased hTERT expression and telomerase activity — an independent confirmation, in a different laboratory and with modern quantitation, of the direction of the 2003 result.
The caveat is equally important. In the cancer lines, telomeres also lengthened — but through activation of the ALT pathway rather than telomerase, and ALT activation was not observed in the normal cells. The authors flagged that the work was in vitro, in two-dimensional cultures, and that in vivo evaluation is still needed. The study strengthens the mechanistic case that Epithalon interacts with telomere-maintenance machinery, while underlining that pathway activation in malignant cells is a safety question to study — not a benefit to claim. A 2025 overview in the International Journal of Molecular Sciences (Araj et al.) reached a similar position: a highly bioactive pineal tetrapeptide, on a predominantly preclinical evidence base.
A second strand of epithalon peptide research concerns chromatin structure rather than telomeres directly. Khavinson’s group reported that Epithalon induces decondensation of heterochromatin near the centromeres in cultured lymphocytes from donors aged 76 to 80 years — re-opening, in aged cells, tightly packed chromosomal regions that condense further with age. Related in vitro work has examined Epithalon’s interaction with histone proteins as a proposed route to gene-expression changes, and a reported inhibition of MMP9 synthesis in aging skin fibroblasts. These findings sit within the broader bioregulator hypothesis — that very short peptides can interact with DNA and histones and modulate gene expression — which remains proposed rather than settled. No primary receptor for Epithalon has been definitively identified.
Epithalon’s pineal origin produced a distinct line of neuroendocrine research — another strand of epithalon peptide research with data behind it. In senescent rhesus monkeys (Khavinson, Goncharova and Lapin, Neuroendocrinology Letters, 2001), evening melatonin in old control animals was roughly half that of young controls, and Epithalon was reported to restore disturbed neuroendocrine regulation — a significant increase in evening melatonin in the old animals (reported at more than three times the corresponding control value) and normalization of the daily cortisol rhythm, while young animals showed no significant melatonin change. Later primate work by Goncharova and colleagues on melatonin rhythm and glucose responses again found effects concentrated in the older animals. That age-dependent pattern recurs across this literature. It is also, notably, primate data from small cohorts — not human clinical evidence.
Epithalon is frequently credited online with large lifespan extensions. The best-documented rodent study of the synthetic peptide itself — Anisimov and colleagues’ study in female Swiss-derived SHR mice (Biogerontology, 2003) — tells a narrower story:
A separate rat study (Anisimov et al., Cancer Letters, 2002) reported an inhibitory effect of Epitalon on chemically induced colon carcinogenesis. The larger lifespan figures often quoted for this compound family come from studies of Epithalamin, the pineal extract — including work in mice, rats and fruit flies dating to the 1990s — and cannot be transferred to the synthetic tetrapeptide. The accurate summary is: Epithalon showed late-life survival and genomic-stability signals in rodents, without extending average lifespan in its best-known mouse study, and it has never been evaluated by the National Institute on Aging’s Interventions Testing Program, the multi-site standard for rodent lifespan claims.
There are no randomized, placebo-controlled human trials of synthetic Epithalon, and no human trial has measured telomeres or telomerase as an outcome of Epithalon administration. The human literature here concerns the extract preparations: Khavinson and Morozov (Neuro Endocrinology Letters, 2003) reported a 6-to-8-year clinical assessment of Epithalamin and Thymalin in 266 elderly subjects, describing normalization across cardiovascular, endocrine, immune and nervous-system indices and lower mortality in treated groups than in controls. Those studies were not conducted to modern Western RCT standards and — critically — they studied the extracts, not AEDG. They are context for the bioregulator program, not evidence about the synthetic peptide sold for research today.
Epithalon is not approved by the FDA, the EMA, or any other major Western regulator for any indication. In September 2023 the FDA placed Epitalon on its Category 2 list of bulk drug substances presenting significant safety risks, which barred its use in compounding under Section 503A. The picture then moved: Epitalon was removed from Category 2 in April 2026, and on July 23–24, 2026 the FDA’s Pharmacy Compounding Advisory Committee (PCAC) voted 7–4, with one abstention, to recommend Epitalon (free base and acetate) for the 503A Bulks List — against FDA staff’s recommendation, whose briefing cited the absence of human safety and pharmacokinetic data. That vote is advisory only: inclusion requires FDA notice-and-comment rulemaking, which has not been completed, so Epitalon cannot currently be compounded under 503A and the vote is not FDA approval. In sport, Epitalon is not named individually on the WADA Prohibited List, but WADA Section S0 prohibits substances with no governmental approval for human therapeutic use, which covers it for tested athletes.
For laboratory work, Epithalon’s profile creates specific verification and handling points:
Yes. Epithalon, Epitalon and Epithalone are alternate spellings of the same synthetic tetrapeptide, Ala-Glu-Asp-Gly. The variation is a transliteration artifact from the original Russian-language literature. None of those names refers to Epithalamin, which is the separate bovine pineal extract.
Cell-culture evidence — from 2003 and an independent 2025 replication — that Epithalon can increase telomerase activity and telomere length in human somatic cells in vitro; primate data on melatonin rhythm in aged animals; and rodent data showing late-life survival and genomic-stability signals without an increase in mean lifespan in the best-documented mouse study. There are no controlled human trials of the synthetic peptide.
No. It is not FDA-approved for any indication. A July 2026 advisory committee vote recommended it for the 503A compounding Bulks List against FDA staff’s recommendation, but that vote is nonbinding, rulemaking is pending, and it is not an approval.
Those figures generally come from studies of Epithalamin, the pineal extract — a different material — or from selective readings of maximum-lifespan rather than mean-lifespan results. In the key SHR mouse study of Epithalon itself, mean lifespan was unchanged while maximum lifespan rose 12.3%.
By HPLC for purity and mass spectrometry for identity against the expected 390.35 Da molecular weight, with the salt form stated. For background on the chromatogram side, see our guide to peptide HPLC purity testing.
Related in the Apex shop: Epithalon research peptide — supplied strictly for laboratory research use.
Disclaimer: This article is for educational and laboratory research purposes only. Epithalon sold by Apex Bio Industries is a research-use-only (RUO) material, supplied strictly for in vitro and laboratory research. It is not approved by the FDA for human or veterinary use, is not a drug, supplement, or cosmetic, and nothing in this article is a claim of efficacy, a dosing recommendation, or an instruction for use in humans or animals.
Selank peptide research starts with an unusual origin story. Most research peptides begin as fragments of a hormone or growth
Retatrutide Peptide Research: The Triple Agonist, TRIUMPH Trials and FDA Status Retatrutide peptide research is where incretin science stopped adding
Sermorelin Peptide Research: GHRH(1-29), GH Pulses and FDA History Sermorelin peptide research occupies an unusual place in the peptide literature:
